VivoSeq
Other

Primary Immune Deficiency

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Primary Immune Deficiency is an early-stage landscape with 0 programs across 3 companies. The most active players are Evolve Biologics, CSL Behring, ADMA Biologics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Evolve Biologics

1 program

Phase 3CSL Behring logo

CSL Behring

0 programs

PreclinicalA

ADMA Biologics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Recruiting2 · 33%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00246857·5,000 enrolled
Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Recruiting·JJohns Hopkins All Children's Hospital·Phase 2·NCT04414046·17 enrolled
Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
Completed·CSL Behring logoCSL Behring·Phase 3·NCT00405184·19 enrolled
Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
Completed·AADMA Biologics, Inc.·Phase 4·NCT03164967·16 enrolled
A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases
Completed·EEvolve Biologics·Phase 3·NCT03238079·63 enrolled
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
Unknown status·UUniversity of South Florida·N/A·NCT01617122·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)